Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael A Postow

Showing results (11-20 of 212) with videos related to

Pageof 22
Sort By:
Clinical Sarcoma Research|October 6, 2012
Inherited gastrointestinal stromal tumor syndromes: mutations, clinical features, and therapeutic implicationsMichael A Postow, Mark E Robson
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 28, 2019
Another Victory for Immune Checkpoint Blockade in Melanoma: Adjuvant Ipilimumab Over InterferonAllison Betof Warner, Michael A Postow
Seminars in Nuclear Medicine|October 16, 2020
Immune-Directed Molecular Imaging BiomarkersNeeta Pandit-Taskar, Michael A Postow
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 16, 2018
Bigger Is Not Always Better: Tumor Size and Prognosis in Advanced MelanomaAllison Betof Warner, Michael A Postow
The New England Journal of Medicine|March 22, 2018
Adverse Events Associated with Immune Checkpoint BlockadeMichael A Postow, Matthew D Hellmann
Oncology (Williston Park, N.Y.)|May 31, 2018
Combination Controversies: Checkpoint Inhibition Alone or in Combination for the Treatment of Melanoma?Allison Betof Warner, Michael A Postow
Cancer Journal (Sudbury, Mass.)|March 29, 2012
Therapeutic implications of KIT in melanomaMichael A Postow, Richard D Carvajal
The Journal of Community and Supportive Oncology|June 28, 2014
Current options and future directions in the systemic treatment of metastatic melanomaKatja A Schindler, Michael A Postow
Cancer Cell|November 1, 2024
Intratumoral vidutolimod in combination with PD-1 blockade in locoregionally advanced melanomaJames W Smithy, Michael A Postow
Current Oncology Reports|February 29, 2016
Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint InhibitionClaire F Friedman, Michael A Postow
Pageof 22

Showing results (11-20 of 212) with videos related to

Sort By:
Pageof 22
Clinical Sarcoma Research|October 6, 2012
Inherited gastrointestinal stromal tumor syndromes: mutations, clinical features, and therapeutic implicationsMichael A Postow, Mark E Robson
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 28, 2019
Another Victory for Immune Checkpoint Blockade in Melanoma: Adjuvant Ipilimumab Over InterferonAllison Betof Warner, Michael A Postow
Seminars in Nuclear Medicine|October 16, 2020
Immune-Directed Molecular Imaging BiomarkersNeeta Pandit-Taskar, Michael A Postow
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 16, 2018
Bigger Is Not Always Better: Tumor Size and Prognosis in Advanced MelanomaAllison Betof Warner, Michael A Postow
The New England Journal of Medicine|March 22, 2018
Adverse Events Associated with Immune Checkpoint BlockadeMichael A Postow, Matthew D Hellmann
Oncology (Williston Park, N.Y.)|May 31, 2018
Combination Controversies: Checkpoint Inhibition Alone or in Combination for the Treatment of Melanoma?Allison Betof Warner, Michael A Postow
Cancer Journal (Sudbury, Mass.)|March 29, 2012
Therapeutic implications of KIT in melanomaMichael A Postow, Richard D Carvajal
The Journal of Community and Supportive Oncology|June 28, 2014
Current options and future directions in the systemic treatment of metastatic melanomaKatja A Schindler, Michael A Postow
Cancer Cell|November 1, 2024
Intratumoral vidutolimod in combination with PD-1 blockade in locoregionally advanced melanomaJames W Smithy, Michael A Postow
Current Oncology Reports|February 29, 2016
Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint InhibitionClaire F Friedman, Michael A Postow
Pageof 22